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Abstract
Introduction: Routine viral load monitoring for HIV-1 management of persons on antiretroviral therapy (ART) has been rec-
ommended by the World Health Organization (WHO) to identify treatment failure. However, viral load testing represents a
substantial cost in resource constrained health care systems. The central challenge is whether and how viral load monitoring
may be delivered such that it maximizes health gains across the population for the costs incurred. We hypothesized that key
features of program design and delivery costs drive the cost-effectiveness of viral load monitoring within programs.
Methods: We conducted a systematic review of studies on the cost-effectiveness of viral load monitoring in low- and middle-
income countries (LMICs). We followed the Cochrane Collaboration guidelines and the PRISMA reporting guidelines.
Results and Discussion: We identified 18 studies that evaluated the cost-effectiveness of viral load monitoring in HIV treat-
ment programs. Overall, we identified three key factors that make it more likely for viral load monitoring to be cost-effective:
1) Use of effective, lower cost approaches to viral load monitoring (e.g. use of dried blood spots); 2) Ensuring the pathway to
health improvement is established and that viral load results are acted upon; and 3) Viral load results are used to simplify HIV
care in patients with viral suppression (i.e. differentiated care, with fewer clinic visits and longer prescriptions). Within the con-
text of differentiated care, viral load monitoring has the potential to double the health gains and be cost saving compared to
the current standard (CD4 monitoring).
Conclusions: The cost-effectiveness of viral load monitoring critically depends on how it is delivered and the program context.
Viral load monitoring as part of differentiated HIV care is likely to be cost-effective. Viral load monitoring in differentiated care
programs provides evidence that reduced clinical engagement, where appropriate, is not impacting health outcomes. Introduc-
ing viral load monitoring without differentiated care is unlikely to be cost-effective in most settings and results in lost opportu-
nity for health gains through alternative uses of limited resources. As countries scale up differentiated care programs, data on
viral suppression outcomes and costs should be collected to evaluate the on-going cost-effectiveness of viral load monitoring
as utilized in practice.
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1 | INTRODUCTION
Routine viral load monitoring for HIV-1 management of per-
sons on antiretroviral therapy (ART) has been recommended
by the World Health Organization (WHO) since 2013 as the
preferred method to identify treatment failure [1]. In the ini-
tial WHO global HIV treatment guidelines (2003), viral load
monitoring was not recommended in low- and middle-income
countries (LMICs) due to the requirements for transportation
of plasma specimens under controlled conditions, limited labo-
ratory infrastructure and availability of the assay, and rela-
tively high cost of viral load monitoring. Instead, clinical
monitoring and/or CD4 count measurement were used to
detect treatment failure [2]. Over the next ten years the avail-
ability of viral load testing increased, the cost of viral load
assays decreased, concerns over resistance accumulation at an
individual and population level grew, methods for viral load
testing on dried blood spot (DBS) specimens were developed,
ART guidelines changed to recommend ART for all HIV-posi-
tive persons, and the cost of first- and second-line ART
decreased [3]. These changes challenged the initial recommen-
dation not to use viral load to monitor the outcome of HIV
treatment. However, viral load testing represents a substantial
cost in resource constrained health care systems in LMICs.
HIV policymakers and program managers are concerned
with affordability and costs because the implications of costs
affect the health care they can provide from their limited
available resources (i.e. costs imply lost opportunities for gen-
erating health) [4]. Cost-effectiveness analysis is a widely-
applied approach to guide whether the health benefits of an
intervention are large enough compared to its costs, such that
its provision from within limited health care resources would
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represent “value for money.” This essentially requires deter-
mining a cost-per-unit of health gained (e.g. per quality-
adjusted life year (QALY)-gained; or disability-adjusted life
year (DALY)-averted) from alternative ways of providing viral
load monitoring in comparison to other approaches (i.e. clini-
cal, routine CD4 monitoring) and, critically, assessing whether
the estimated cost per unit of health gain represents value
against a benchmark.
Several published studies have concluded that routine viral
load monitoring is cost-effective in LMICs by referencing the
cost per DALY to a benchmark of one to three times gross
domestic product (GDP) per capita of a country [5–7]. How-
ever, given the level of resource constraints in countries, such
benchmarks are now widely recognized as being inappropriate
to inform value for money assessments and risk lowering pop-
ulation health through diverting investments away from
greater priorities [8,9].
Suitable benchmarks are context-specific and can be difficult
to ascertain. An emerging stream of research has shown that,
for general health care, values are much lower than previous
acknowledged – for example ~$60 to 100 in Malawi – due to
high levels of unmet health needs [10,11]. However, HIV
interventions remain overwhelmingly reliant on overseas aid
which is specifically ear-marked for this condition, and the
overall level of such aid means in practice that HIV-related
interventions may be cost-effective at higher values than this
(e.g. $300 to $500) [12–14]. A number of papers sought to
specifically assess whether viral load monitoring would
improve population health compared to committing the
required resources to continued scale-up of ART and have
often found that it would not [15,16]. The central challenge
then is whether and how viral load monitoring may be deliv-
ered such that it would justifiably constitute a component of
HIV care, even in the context of the higher cost effectiveness
threshold operating for HIV interventions, and does not divert
resources away from other priority health care activities that
could generate greater health benefits.
We conducted a review of recent studies on the cost-effec-
tiveness of viral load monitoring in LMICs. Our hypothesis
was that key assumptions about program design and costs of
monitoring drive the cost-effectiveness of programs that
incorporate viral load monitoring. The primary review objec-
tive was to identify characteristics of programs that make viral
load testing more or less likely to be cost-effective and con-
tribute to improvements in population health, recognizing
there are other calls on limited HIV program resources.
2 | METHODS
We reviewed cost and cost-effectiveness studies of viral load
testing in HIV treatment programs in LMICs and summarized
the key factors that determine cost-effectiveness. We followed
Cochrane Collaboration guidelines in conducting our review
[17], and PRISMA guidelines in reporting results [18].
2.1 | Search strategy, selection of data, synthesis
We conducted an electronic search of the PubMed database
on 14 February 2017 for studies published from 1 January
2000, onwards, using the following MeSH terms: (“viral
load”(MeSH Terms) OR “viral”(All Fields) AND “load”(All
Fields) OR “viral load”(All Fields)) AND (“economics”(Subhead-
ing) OR “economics”(All Fields) OR “cost”(All Fields) OR “costs
and cost analysis”(MeSH Terms) OR (“costs”(All Fields) AND
“cost”(All Fields) AND “analysis”(All Fields)) OR “costs and cost
analysis”(All Fields)). The EMBASE data base was searched
using the equivalent search terms. Reference lists of papers
meeting criteria were hand searched for additional articles. To
ensure that we included unpublished data, abstracts were
reviewed from the past meetings of the Conference on Retro-
viruses and Opportunistic Infections (CROI).
Abstracts and full-text articles of potentially relevant studies
were reviewed independently by two authors (N.T. and R.V.B.)
against pre-defined criteria. Papers were eligible for inclusion
if the analysis was conducted in a LMIC setting and a cost-
effectiveness result for viral load monitoring was included.
Data were extracted using a standardized data extraction
form. Discrepancies regarding eligibility of papers were dis-
cussed and consensus reached. The methodological quality of
included studies was reviewed by N.T. and R.V.B. Discrepan-
cies in quality rating were discussed and consensus reached.
Studies were rated as low, moderate, or high risk of bias,
dependent on whether they met standard guidelines for
health economic evaluation reporting [19]. The study results
were summarized and synthesized for discussion; a quantita-
tive summary statistic was not estimated for the cost-effec-
tiveness of viral load monitoring. To assess factors that
increased the cost-effectiveness of viral load monitoring, we
reviewed the model and program parameters that determined
cost-effectiveness relative to the base case and qualitatively
summarized and grouped the factors into three main themes.
3 | RESULTS
The electronic search yielded 1248 results of which 1165
were unique abstracts. We identified 23 manuscripts and four
conference abstracts for review of which 18 met the search
criteria and addressed the cost-effectiveness of viral load
monitoring (Table 1).
The studies were conducted in a range of LMIC settings
(sub-Saharan Africa, Cameroon, Uganda, South Africa, Zambia,
Zimbabwe, Cote d’Ivoire, Vietnam and Thailand). Two health
economic analyses were based on clinical trials conducted in
Uganda and Cameron [20,21]. The remaining analyses collated
surveillance data, worked closely with programs, and reviewed
the literature to obtain parameters for health economic mod-
eling. Study outcomes were reported as the cost per DALY
averted, cost per QALY gained, cost per life year gained (LYG),
and/or year of life saved (LYS).
Cost-effectiveness analyses were conducted from 2004
[22] and projected out to 2035 [23]. Twelve [5,22–32] of the
18 studies found that viral load monitoring was cost-effective.
Studies used different thresholds to determine cost-effective-
ness combined with variation in the unit costs resulted in
marked heterogeneity between the results. The unit cost of
viral load testing varied in the analysis from $5.80 [25] to
$103.88 [27] per test, and the annual cost of first line ART
and second line ART varied also from $108.18 [5] to $462.47
[30] and $239.31 [33] to $2071.33 [30], respectively (2017
USD). The range in the costs for viral load assays and ART is
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Table 1. Studies estimating the cost-effectiveness of viral load (VL) monitoring
First author Location Year studied
Key features
modelled
Authors’
conclusion
on cost-
effectiveness+
Factors that make VL testing
more cost-effective
Incremental cost-effectiveness
ratio (ICER)
Kahn [21] Tororo,
Uganda
2001 to 2002 Randomized trial Definite no VL testing was not effective in
this RCT (no evidence of
health benefit)
Clinical + CD4 + VL monitoring
vs. Clinical + CD4 monitoring:
$5181 per DALY averted
Schneider [31] Thailand 2001 to 2009 Heterogeneity in VL
Virologic failure
Effect of VL on
differentiation of care
^Qualified yes Lower cost of ART Annual monitoring after single
screen at six months vs.
Supplying only first-line ART for
ten years (with ART costs):
$68,084 per QALY
Annual monitoring after single
screen at six months vs.
Supplying only first-line ART for
ten years (without ART costs):
$7224 per QALY
Bishai [22] Sub-Saharan
Africa
2004 (Cost data) Heterogeneity in VL
Virologic failure
^Qualified yes Second line treatment would
have to be available
Cost of VL testing would have
to be reduced to $14 per
test to have same median
ICER as CD4 testing
compared to clinical
monitoring
VL vs. CD4 monitoring (second
line unavailable): $16,139 per
QALY
VL vs. CD4 monitoring (second
line available): $14,670 per
QALY
Vijayaraghavan
[32]
South
Africa
2005 Heterogeneity in VL
Virologic failure
Variation switching
to second line in
first line failures
Definite yes Treating patients with VLs
>100,000 copies/ml to
reduce HIV transmission by
“highly efficient transmitters”
Use of VL testing every six
months vs. WHO guidelines:
$7860 per QALY
Increased VL testing frequency
(every three months) vs. WHO
guidelines: $41,286 per QALY
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Table 1. (Continued)
First author Location Year studied
Key features
modelled
Authors’
conclusion
on cost-
effectiveness+
Factors that make VL testing
more cost-effective
Incremental cost-effectiveness
ratio (ICER)
Pham [30] Vietnam 2005 to 2013 Resistance
Virologic failure
^Qualified yes VL testing every two years
and individuals with VL
>1000 copies/ml and
detectable HIV drug
resistance placed on second
line ART
Lower cost of second line ART
Low cost POC-VL and
resistance tests
WHO recommendations for VL
monitoring (six months after
treatment initiation and every
12 months thereafter) vs.
Status quo (no VL monitoring):
$5243 per DALY averted
Kimmel [27] Co^te d’Ivoire 2006 Heterogeneity in VL
Resistance
^Qualified yes HIV RNA test <$90
Decrease in second line
efficacy due to time spent
on failing first line ART is
greater than 1% per month
Cost of second line ART <
$300
VL monitoring (test cost = $50 to
$87) vs. Cotrimoxazole
prophylaxis for opportunistic
infections: $1990 to 2920 per
YLS
Boyer [20] Cameroon 2006 to 2010 Clinical Trial Qualified no Lower priced generic in-house
assay
Use VL assay for patients with
CD4 <200 cells/ll
Clinical monitoring vs.
VL + CD4 + clinical monitoring
(Abbot RealTime HIV-1 assay):
$4768 per LYS
Clinical monitoring vs.
VL + CD4 + clinical monitoring
(Generic assay): $3339 per LYS
Bendavid [24] Cape Town area 2007 Heterogeneity in VL
Virologic failure
^Qualified yes Lower price of VL testing
Possibly reduced HIV
transmission (not modelled)
Fewer accumulated resistance
mutations (not modelled)
Higher rate of virologic failure
VL monitoring + CD4 vs. CD4:
$5414 per LYG
Every three months vs. every six
months: $100,000 per LYG
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Table 1. (Continued)
First author Location Year studied
Key features
modelled
Authors’
conclusion
on cost-
effectiveness+
Factors that make VL testing
more cost-effective
Incremental cost-effectiveness
ratio (ICER)
Phillips [34] Lower to middle
income countries
2008 Heterogeneity in VL
Virologic failure
Resistance
Variation in switching
to second line in first line failures
Qualified no Lower cost of second line ART VL >500 copies/ml vs. Switch
after WHO stage four event:
$1500 per LYG
VL >10,000 copies/ml vs. Switch
after WHO stage four event:
$4011 per LYG
Scott
Braithwaite [16]
Sub-Saharan Africa 2008 (Cost data) Virologic failure
Heterogeneity in VL
Qualified no ICER for VL testing better
when first and second line
costs are equal
Use routine virological testing
when ART is already
initiated at 500 cells/ll and
coverage targets have been
met
Low cost VL testing
Six monthly VL testing,
switching threshold at
1000 copies/ml is the only
strategy on the efficient
frontier
VL monitoring (10,000 copies/ml
to 1000 copies/ml threshold)
vs. Starting ART at CD4 count
200 cells/ll: $4723 to $25,370
per QALY
Estill [5] LMIC (Cost data can be
updated for specific
setting)
2010 Variation in switching to second line
in first line failures
Resistance
Effect of VL on differentiated care
Virologic failure
Heterogeneity in VL
Qualified no Routine VL monitoring cost-
effectiveness depends on
cost of second line ART
POC VL cost-effectiveness
improved if first and second
line ART prices are close
Targeted VL monitoring is
cost-efficient only if second
line costs are much higher
than first line, and routine
VL monitoring does not
prevent failure
VL monitoring vs. Clinical
monitoring: $951 to $5813 per
DALY averted
POC-VL (every six to twenty-four
months) vs. CD4 monitoring
(irregular every six months,
every six to twenty-four
months): $426 to $33,515 per
DALY averted
Lab-VL (every six to twenty-four
months) vs. CD4 monitoring
(irregular every six months,
every six to twenty-four
months): $984 to $8862 per
DALY averted
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Table 1. (Continued)
First author Location Year studied
Key features
modelled
Authors’
conclusion
on cost-
effectiveness+
Factors that make VL testing
more cost-effective
Incremental cost-effectiveness
ratio (ICER)
Hamers [26] South Africa 2011 Virological failure Definite yes Reduced accumulation of drug-
resistance mutations,
reduced incidence of
opportunistic infections and
mortality, increased
economic productivity,
reduced HIV transmission
VL-only every six months vs.
Symptom-based approach:
$3183 per LYG
VL-only every 12 months vs.
Symptom-based approach:
$5319 per LYG
Estill [25] LMIC (Cost data can be
updated for specific
setting)
2012 Heterogeneity in VL
Virologic failure
^Qualified yes Include reductions in HIV
transmission with
suppression
Lower cost of second line ART
and VL
Risk of virological failure with
monitoring strategy (reduced
by VL monitoring compared
to clinical/CD4 monitoring)
Use POC-VL test level of
detection criteria of
1000 copies/ml to reduce
unnecessary switches to
second line ART
More accurate detection of
treatment failure and faster,
more appropriate switching to
second line:
$4010 to $9230 per QALY vs.
clinical monitoring and $5960
to $25,540 vs. CD4 monitoring
Taking transmission into account +
More accurate detection of
treatment failure and faster,
more appropriate switching to
second line:
$2450 to $5830 per QALY vs.
clinical monitoring and $2230
to $10,380 vs. CD4 monitoring
Risk of virologic failure twice as
high with clinical or CD4
compared to VL monitoring +
Taking transmission into
account + More accurate
detection of treatment failure
and faster, more appropriate
switching to second line:
$960 to $2500 per QALY vs.
clinical monitoring and cost
saving $2460 per QALY vs.
CD4 monitoring
B
arn
ab
as
R
V
e
t
al.
Jo
u
rn
a
l
o
f
th
e
In
tern
a
tio
n
a
l
A
ID
S
S
o
ciety
2
0
1
7
,
2
0
(S
7
):e
2
5
0
0
6
h
ttp
://o
n
lin
e
lib
rary.w
ile
y.co
m
/d
o
i/1
0
.1
0
0
2
/jia2
.2
5
0
0
6
/fu
ll
|
h
ttp
s://d
o
i.o
rg
/1
0
.1
0
0
2
/jia2
.2
5
0
0
6
5
5
Table 1. (Continued)
First author Location Year studied
Key features
modelled
Authors’
conclusion
on cost-
effectiveness+
Factors that make VL testing
more cost-effective
Incremental cost-effectiveness
ratio (ICER)
Keebler [15] Zambia 2012 Presents results from three different
models
Heterogeneity in VL
Resistance – HIV Synthesis model
(Phillips), Braithwaite and
colleagues
Variation in switching to second line
in first line failures
Virological failure
Qualified no VL monitoring after high ART
coverage is achieved
Lower second line ART cost
Lower test costs
Targeted VL strategy
VL every 12 months vs. VL every
36 months:
Braithwaite (20 years): $6018.83
per DALY averted
HIV Synthesis (15 years):
$3413.8 per DALY averted
Estill (five years): $3760 per
DALY averted
Negoescu [28] Uganda 2013 Virologic failure
Effect of VL on differentiated care
^Qualified yes Client centered and tailored to
country GDP: Adjusting VL
monitoring intervals of HIV
patients on ART according
to individual patient
characteristics, disease
dynamics, behavior, and
GDP.
Implementation in high
resource settings
Adaptive VL optimized to 19
GDP threshold vs. monitoring
every 24 months: $491 per
QALY
Adaptive VL optimized to 39
GDP threshold vs. adaptive VL
optimized to 19 GDP
threshold: $1311 per QALY
Ouattarra [29] Co^te d’Ivoire 2013 to 2017 Virologic failure
Effect of VL on differentiated care
Heterogeneity in VL
Definite yes Adaptive VL ICER <19 GDP if
second line ART and VL
costs decreased to $156
and $13
Sensitive to initial CD4 count
of cohort
Lower HIV transmission rate
due to monitoring (not
modelled)
Adaptive VL vs. VL confirmation:
$4100/YLS (2013 USD)
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Table 1. (Continued)
First author Location Year studied
Key features
modelled
Authors’
conclusion
on cost-
effectiveness+
Factors that make VL testing
more cost-effective
Incremental cost-effectiveness
ratio (ICER)
Phillips [35] Zimbabwe 2015 to 2025 Paper was primarily focused on
whether use of drug resistance
testing was likely to be cost
effective as part of ART monitoring
strategy.
Variation in switching to second line
in first line failures
Virologic failure
Resistance
Heterogeneity in VL
Qualified no Most effective strategy for
DALYs averted was VL
monitoring without
confirmation
VL monitoring with no
confirmation vs. no monitoring,
no second line: $2113 per
DALY averted
Phillips [23] Zimbabwe 2015 to 2035 Variation in switching to second line
in first line failures
Virologic failure
Resistance
Heterogeneity in VL
Effect of VL on differentiated care
^Qualified yes With $22 viral-load test cost,
annual savings of $30
needed to make program
cost-effective. Reducing
visits from every one to
three months to every six
months or every nine to
twelve months should
enable these savings.
Reduction in non-ART
program costs
Use VL monitoring less
frequently than every
12 months (caveat: health
risks with such infrequent
VL monitoring not well
understood)
DBS VL monitoring every
12 months vs. No monitoring:
$326 per DALY averted ((if
used to differentiate care and
reduce clinic visit costs)
^Qualified yes – the authors’ overall conclusion was that viral load monitoring was cost effective, but that this was conditional on the existence of certain conditions, +The author’s conclusions
on cost effectiveness depend on the choice of cost effectiveness threshold – the appropriate threshold is now recognised as being lower than had previously been supposed, particularly when
using the 19 or 39 GDP criteria. ART, antiretroviral therapy; DALY, disability-adjusted life years; GDP, gross domestic product; LYG, years of life gained; LYS, life years saved; QALY, quality-
adjusted life years; VL, viral load; YLG, years of life gained; WHO, World Health Organization; LMIC, low- and middle-income countries.
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due to agreements with manufacturers, volume of demand,
advocacy, human resource costs, and calendar time of the
study (with costs generally falling over time). Studies that did
not include the transmission benefits of viral suppression may
have underestimated the cost-effectiveness of viral load moni-
toring [27,29]. Neither clinical trial found a beneficial health
impact of viral load monitoring on clinical outcomes [20,21],
thus the change in costs was not balanced by an improvement
in the health outcomes with the intervention. The clinical trials
were conducted prior to lower cost viral load testing and ART
recommended for all HIV-positive persons.
4 | DISCUSSION
We found three main factors that make it more likely for viral
load monitoring to be cost-effective (Table 2): 1) Use of effec-
tive, lower cost approaches to viral load monitoring; 2)
Ensuring the pathway to health improvement is established
and that viral load results are acted upon; and 3) Simplifying
HIV care and including viral load monitoring to facilitate differ-
entiated care.
4.1 | Effective, low-cost approaches to viral load
monitoring
Several factors can ensure the cost of viral load testing
and the fully loaded cost (all the costs of conducting a
test) is as low as possible: choosing an efficient specimen
for measuring viral load such as DBS, using an assay and
threshold that strikes the right balance between the risks
of missing detectable viral load and switching unnecessar-
ily, and limiting the frequency of viral load monitoring
[16,22–25,27,29–31]. In 2014, Roche introduced a ceiling
price for PCR laboratory based viral load testing of $9.40
(and a fully loaded cost of $20) which, at a quarter of the
Table 2. Characteristics that support cost-effective viral load (VL) monitoring for HIV: 1) low cost approaches; 2) pathway to
impact; and 3) differentiated care
Characteristic Comment Ref.
1 Effective, low cost approaches to VL monitoring
1 Lower average unit costs:
a VL assays,
b Other factors contributing to fully loaded
costs for VL monitoring (e.g. personnel,
transport, facility costs etc.),
c Dried blood spots (DBS)
replacing plasma specimens
d Second line ART
• Roche introduced $9.40 price ceiling for VL testing in 2014
(fully loaded $20).
• DBS allows more feasible collection and transport for speci-
mens in challenging conditions, at lower cost compared to
transportation of plasma specimens.
• Decreases in the cost of protease inhibitor based second line
ART regimens would decrease the cost of changing to second
line regimens if clients are failing first line therapy.
• Decreases in these variable unit costs can drive cost-effective-
ness.
[16,22–25,27,29–31]
1.2 Less frequent VL testing • VL monitoring six months after initiation and then bi/annually
was cost-effective compared to six monthly monitoring.
• Two-yearly testing vs. annual testing increases cost-effective-
ness
[1,23,29]
2 Pathway to impact: Action based on VL results
2 Action based on VL results • Most models assume that the VL results are acted on in a
timely manner with adherence counseling, resistance testing if
available, and prompt switch to second line ART which
increases viral suppression.
• Assuming that a high proportion of tests fail or the results are
not received dramatically decreases the likelihood of cost-effec-
tiveness
• Timely (<six months) switch to second line ART in people with
consecutive viral load levels >1000 copies/ml. which minimizes
resistance and clinical failure.
[23]
3 Differentiated care for HIV
3 VL informed differentiated care • Potential to save costs from fewer clinical visits, longer pre-
scriptions, clinical visits with regular clinical staff for clients
who achieve viral suppression and do not require complex spe-
cialty care.
[15,23,36–39]
ART, antiretroviral therapy.
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previous cost, has increased the cost-effectiveness of viral
load testing [29]. Lastly, point-of-care viral load testing
could well be more cost-effective if the real-time response
to the results which such testing enables improves clinical
care.
In addition to the costs of viral load testing itself, analyses
have shown that downstream costs (in particular second line
ART) notably affect the cost-effectiveness of viral load moni-
toring. Although costs of protease inhibitor based regimens
have fallen markedly in recent years (from $600 to $205 per
patient year in 2016 [40]), these are still very high for low
resource health care systems – limiting the potential for viral
load monitoring to be cost effective. The incremental cost-
effectiveness ratio (ICER) of viral load testing changed from
$4100 to <1500/year of life saved when considering a range
of lower viral load testing and ART costs in Cote d’Ivoire [29].
Similarly, cost-effectiveness analyses that account for the
decrease in transmission benefits with ART better estimate
the full health gains compared to analyses only looking at indi-
vidual benefits and cost.
4.2 | Pathways to impact: action based on viral
load results
There are inevitably challenges in implementing and acting
upon viral load testing and these need to be considered in
assessing cost-effectiveness. Specimens need to be trans-
ported in an efficient manner to accredited laboratories,
results relayed to clinicians and clients, and the results acted
on promptly with adequate access to second line ART. Most
analyses that find viral load monitoring to be cost-effective
assume that the viral load results are acted on in a timely
manner (either immediately or less than six months). Protocols
that delineate the next steps for a client on ART with a
detectable viral load for example adherence counseling, viral
load retesting three months after adherence counseling, resis-
tance testing (where available) if viral load is still detectable
despite adherence, and switching to second line ART in a
timely manner, increase clinical effectiveness and decrease the
emergence and transmission of resistance mutations. Some cli-
ents may require more regular visits and monitoring for com-
plex disease or comorbidities. Notably, even with viral load
monitoring, switching to second line ART generally does not
occur within the timeframe assumed by most mathematical
models of HIV and the proportion of people who are on sec-
ond line regimens is generally below 5% [23]. Phillips and col-
leagues estimated that even avoiding a three-month delay
through point-of-care testing, could increase health benefits
by 6% with no additional costs. Also, both randomized studies
of the cost-effectiveness of viral load testing found viral load
testing not to be cost-effective for monitoring [20,21], a note
of caution that implementation must emulate the modelled
scenarios to meet the cost-effectiveness thresholds. The cost-
effectiveness of viral load monitoring hinges on adequate ser-
vices to deliver clinical benefits.
4.3 | Differentiated care for HIV
Differentiated care for HIV allows simplifying of protocols for
persons well controlled on ART, with client responsive viral
load testing (six months after initiation and then annually
unless clinically indicated) providing feedback to inform on-
going individual and program effectiveness. This also supports
viral load monitoring replacing CD4 count monitoring, spacing
appointments, providing longer prescription refills, task shift-
ing, community-based ART, testing using DBS specimens to
simplify specimen transport, and using clinical care resources
for complex clinical cases and clients who are not suppressed
on ART. In this differentiated care context, viral load monitor-
ing enables greater comfort with less clinical engagement. The
cost of viral load testing can be offset by savings in the clinical
visit costs. Thus, differentiated care with viral load monitoring
can save costs with greater health gains compared to standard
of care clinic management (for a simulated model population of
Zimbabwe over 20 years, viral load monitoring and differenti-
ated care had a cost saving of $139 million and 580,000
DALYS compared to CD4 monitoring, which represents a dou-
bling of the health gain at more than a third less of the cost
[23]). It is notable that the distinction between standard of
care clinic HIV management and differentiated care is blurring
as some, but not all, aspects of differentiated care are incorpo-
rated into clinic care such as chronic medication refills without
clinic visits available for clients on ART in South Africa. Impor-
tantly, for differentiated care, viral load monitoring provides
program level evidence on whether reduced clinical engage-
ment impacts individual and public health outcomes.
Cost-effectiveness studies aim to inform the allocation of
limited resources. This requires estimating the incremental
costs of alternative interventions (e.g. viral load vs. CD4 vs.
clinical-only monitoring) and the incremental health benefits (e.g.
QALYs-gained or disability adjusted life years (DALYs)-
averted); then assessing whether the cost-per-unit of health
improvement represents sufficient value, compared to other
claims on limited resources. These can all change depending
upon how and where viral load monitoring is delivered, so any
universal claims to cost-effectiveness are misguided and it is
vital to understand the place of viral load monitoring within
HIV programs and how it may facilitate design of programs to
improve population health from within the resources available.
The results table (Table 1) illustrates that the ICER needs
to be interpreted within the context of the analysis. First, the
ICERs per QALY gained or DALY averted, even though each
measure is in the same units, are not directly comparable
unless the same strategies are compared, that is whether viral
load testing is compared with clinical staging and/or CD4
count and underlying programmatic assumptions (indicated in
the ICER column). Second, the threshold for what is consid-
ered cost-effective does vary as is illustrated in the interpreta-
tion of the results (conclusion column) which reflects the
perspective and setting of the analysis.
4.4 | Looking ahead: likely future programmatic
changes that impact viral load cost-effectiveness
Lastly, notable programmatic changes are likely to impact
cost-effectiveness of viral load testing, specifically changing to
ART regimens with a high barrier to resistance [27] such as
integrase inhibitors. The integrase inhibitor, dolutegravir, for
example, has a higher barrier to resistance than current first
line efavirenz based regimens, which could decrease the clini-
cal benefits of viral load monitoring since resistance is encoun-
tered less frequently. The combination of ART formulations
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and monitoring strategy should offer the greatest health gains
for the cost. With alternative monitoring tests, for example
detecting TDF/TAF in urine, viral load monitoring might only
be required for clients without detectable TDF/TAF or other
clinical concerns. As new regimens and models for care are
rolled out, the cost-effectiveness of viral load monitoring will
need to be reassessed on a continual basis.
5 | CONCLUSIONS
The cost-effectiveness of viral load monitoring is critically
dependent on context. Viral load monitoring in differentiated
care programs provides evidence that reduced clinical engage-
ment, where appropriate, is not impacting health outcomes
[23]. To achieve this goal of cost effective viral load monitoring,
differentiated care programs will need to be scaled up to
achieve the gains of cost saving – introducing viral load moni-
toring without differentiated care can result in lost opportunity
for health gains through an alternative use of resources. As
countries scale up differentiated care programs, data on viral
load outcomes and cost are essential to evaluate the on-going
cost-effectiveness of viral load monitoring in practice. Efforts
to standardize this reporting and rapid analysis would facilitate
the adoption of successful differentiated care strategies.
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